Haemonetics has a total of 1038 patents globally, out of which 612 have been granted. Of these 1038 patents, more than 44% patents are active. United States of America is where Haemonetics has filed the maximum number of patents, followed by Europe and Japan. Parallelly, United States of America seems to be the main focused R&D centre and also is the origin country of Haemonetics.
Haemonetics was founded in the year 1971. The Company designs, manufactures and markets automated blood processing systems. The Company’s products are for use in surgical blood salvage, blood component collections and plasma collections. As of June 2023, the market cap of Haemonetics is $4.46 Billion.
Do read about some of the most popular patents of Haemonetics which have been covered by us in this article and also you can find Haemonetics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Haemonetics patent portfolio.
How many patents does the founder and the CEO of Haemonetics have?
The founder Jack Latham has 1 patent and CEO Christopher Simon has 0 patent.
How many patents does Haemonetics have?
Haemonetics has a total of 1038 patents globally. These patents belong to 241 unique patent families. Out of 1038 patents, 457 patents are active.
How Many Patents did Haemonetics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Haemonetics Applications Filed | Haemonetics Patents Granted |
| 2023 | 3 | 18 |
| 2022 | 13 | 28 |
| 2021 | 19 | 55 |
| 2020 | 15 | 39 |
| 2019 | 66 | 23 |
| 2018 | 28 | 23 |
| 2017 | 46 | 19 |
| 2016 | 46 | 35 |
| 2015 | 41 | 41 |
| 2014 | 58 | 40 |
| 2013 | 41 | 21 |
| 2012 | 27 | 46 |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
| Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
| US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
| US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
How many Haemonetics patents are Alive/Dead?
How Many Patents did Haemonetics File in Different Countries?
Countries in which Haemonetics Filed Patents
| Country | Patents |
| United States Of America | 247 |
| Europe | 142 |
| Japan | 126 |
| Germany | 86 |
| China | 78 |
| Hong Kong (S.A.R.) | 54 |
| Australia | 37 |
| Canada | 25 |
| Austria | 20 |
| India | 18 |
| Korea (South) | 17 |
| Russia | 14 |
| Italy | 9 |
| Singapore | 8 |
| Brazil | 8 |
| Taiwan | 7 |
| Spain | 6 |
| New Zealand | 4 |
| Viet Nam | 4 |
| Israel | 3 |
| Hungary | 3 |
| Norway | 3 |
| Poland | 2 |
| Mexico | 2 |
| Denmark | 1 |
| South Africa | 1 |
| Saudi Arabia | 1 |
| Switzerland | 1 |
| United Kingdom | 1 |
| Malaysia | 1 |
Where are Research Centres of Haemonetics Patents Located?
10 Best Haemonetics Patents
US6641592B1 is the most popular patent in the Haemonetics portfolio. It has received 586 citations so far from companies like Lsi Solutions, Neotract and Usgi Medical.
Below is the list of 10 most cited patents of Haemonetics:
| Publication Number | Citation Count |
| US6641592B1 | 586 |
| US6537819B2 | 142 |
| US6558307B2 | 127 |
| US6613573B1 | 111 |
| US6629919B2 | 95 |
| US6743192B1 | 94 |
| US6508778B1 | 93 |
| US20070059840A1 | 92 |
| US20030119177A1 | 87 |
| US6656207B2 | 86 |
How many inventions of other companies were rejected due to Haemonetics patents?
The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to Haemonetics invention. They couldn’t because Haemonetics had protected those before them.
Examiners at the USPTO referred 84 Haemonetics patents in 389 rejections (35 USC § 102 or 35 USC § 103 types).
The top citing companies in the Haemonetics patent portfolio are Fenwal, Terumo and Cardiva Medical.
List of the Companies whose Patents were rejected citing Haemonetics –
| Company | Number of Patent Applications that faced Rejection Citing Haemonetics Patents | Number of Rejections (102 & 103) |
| Fenwal | 11 | 26 |
| Terumo | 6 | 17 |
| Cardiva Medical | 6 | 13 |
| C A Casyso | 3 | 9 |
| St Jude Medical Puerto Rico | 3 | 6 |
| P Tech | 3 | 4 |
| Phillips Medical | 3 | 4 |
| Geneasys | 3 | 3 |
| Hemosonics | 3 | 12 |
| Oxford Finance | 2 | 5 |
Count of 102 and 103 Type Rejections based on Haemonetics Patents
Top Haemonetics Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US8157792B2 | 9 |
| US7854845B2 | 8 |
| US6641592B1 | 7 |
| US20070219826A1 | 6 |
| US20100168767A1 | 6 |
| US8758321B2 | 6 |
| US7571744B2 | 5 |
| US7574076B2 | 5 |
| US7449679B2 | 4 |
| US7993366B2 | 4 |
| US7691127B2 | 4 |
| US7460240B2 | 4 |
| US7303605B2 | 4 |
| US20060174385A1 | 3 |
| US8775209B2 | 3 |
What are Haemonetics‘s key innovation segments?
What Technologies are Covered by Haemonetics?
The chart below distributes patents filed by Haemonetics